Loading
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.
Direct links plus the targets, companies, and technologies of this cancer's products.
Shares Receptor conversion: when the receptors change between the primary and a recurrence, DESTINY-Breast06, DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, HER2-low and HER2-ultralow and the tag subtype-page.
Shares Sacituzumab govitecan, Olaparib, Trastuzumab deruxtecan, Liquid biopsy (ctDNA) and the tag subtype-page.
Shares Ipatasertib, EMBRACA, OlympiAD, Talazoparib and the tag subtype-page.
Shares PTEN loss, Everolimus and the tag subtype-page.
Shares PTEN loss, Abemaciclib and the tag subtype-page.
Shares Abemaciclib, Olaparib, Trastuzumab deruxtecan and the tag subtype-page.
Shares Olaparib, Trastuzumab deruxtecan and the tag subtype-page.
Shares PTEN loss, Capivasertib and the tag subtype-page.
The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.